Last week I was asked over lunch what I thought was the single biggest risk for investors. Fiddling with my slightly overchewy steak I debated whether to mutter the usual dread words (inflation, equities sell off) before deciding on Taiwan… Continue reading →
You might have got the impression that prices are rising everywhere, especially within the commodities complex. That’s only partially true though. The main benchmark commodity index, the S&P GSCI (ER) rose by 6.0% in September, which is a relatively big… Continue reading →
Insider fund buying It’s always interesting to track who in fund land is eating their own cooking or more accurately insiders buying fund stock. I’d argue that’s especially the case at the moment with markets looking a bit fragile. Investec… Continue reading →
Today I’ve got a quick smorgasbord of fund updates on some of my more adventurous investment trusts. First up, Killik and Co’s excellent research guru nicely sums up why I’m still enthusiastic about India Capital Growth (IGT). If we’re honest… Continue reading →
If you haven’t already done so, I thoroughly recommend visiting the new Doceo.tv website. I mentioned the website in a Money Week article a while back and so impressed was I in this new video-based proposition that I thought I’d… Continue reading →
My FT column this weekend and my Citywire column this week harp on about the same topic – how to diversify your portfolio in case of market turbulence. The idea here is to find genuine alternatives. On Friday I’ll publish… Continue reading →
September was something of a disappointment again for equity investors, although I think it could have been much, much worse. According to analysts at S&P Dow Jones , their aggregate measure of major markets posted its first decline (-4.08%) since… Continue reading →
I’ve been thinking long and hard about the big ideological changes in China, and what they mean for investors. What’s prompted me to ponder this huge question is that much of the language coming out of China is wearily familiar,… Continue reading →
I was chatting recently with an investor about why I liked life sciences and biotech funds. I’m a long term bull, with life sciences exposure hovering at something between 15 and 25% at the portfolio level. Favourite funds include RTW… Continue reading →
© 2024 The Adventurous Investor